Core Insights - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historic high [1] - The total value of innovative drug licensing transactions from China exceeded $130 billion in 2025, with over 150 transactions, also a historic high [2] Group 1: Innovative Drug Approvals - The 76 approved innovative drugs in 2025 include 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [1] - Among the 47 chemical drugs, 38 are domestic innovations, representing 80.85% of the total [1] - For the 23 biological products, 21 are domestically developed, accounting for 91.30% [1] Group 2: Licensing Transactions - The total amount for innovative drug licensing transactions in 2025 was over $130 billion, nearly doubling from $51.9 billion in 2024 [2] - The number of licensing transactions increased from 94 in 2024 to over 150 in 2025 [2] - China's pipeline of new drugs accounts for approximately 30% of the global total, ranking second worldwide [2] Group 3: Future Initiatives - Starting in 2026, the National Medical Products Administration (NMPA) will implement more measures to accelerate the development of innovative drugs [3] - The NMPA plans to prioritize review resources for urgently needed clinical products, especially those with new mechanisms and targets [3] - Additional support will be provided through breakthrough therapy designations, conditional approvals, priority reviews, and special approvals to expedite the market entry of urgently needed drugs [3]
2025年我国批准创新药76个 对外授权破千亿美元
Yang Shi Xin Wen·2026-01-03 06:41